ERBB2 and breast carcinoma: Additionally, the recommended dose of PLD is 50 mg/m2 day 1 every 4 weeks as one of the preferred regimens for stage IV/recurrent metastatic HER2-negative breast cancer by the National Comprehensive Cancer Network clinical guidelines for breast cancer [38].